Companies: 10,795·Total market cap: $144.5T
eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc.

EFTROTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$941
P/E Ratio
52W High$0.01
52W Low$0.0002
Overview

eFFECTOR Therapeutics, Inc. (EFTR) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · EFTR · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-14.46eftr eps ttm · eftr earnings per shareEarnings history
PE Ratio (TTM)eftr pe ratio ttm · eftr price to earningsPE Ratio deep dive
Revenue (TTM)162000.00eftr revenue ttm · eftr annual revenueFull revenue history
Dividend YieldNo Dividenddoes eftr pay dividends · eftr dividend yieldDividend history
Shares Outstanding2.2Meftr shares outstanding · eftr floatShares outstanding history
Next EarningsAug 12, 2026Est.eftr earnings date · eftr next earningsEarnings history

Financial Snapshot

Full Financials
FY 2023Revenue$0.00▼ 100.00% YoY
202120222023
effector therapeutics, inc. revenue · eftr revenue 2023
FY 2023Net Income-$35.8M▼ 177.02% YoY
202120222023
effector therapeutics, inc. net income · eftr profit 2023
FY 2023EPS$-16.37▼ 108.54% YoY
202120222023
eftr eps · effector therapeutics, inc. earnings per share 2023
TTM:Revenue: $162000.00Net Income: -$34.6MEPS: $-14.46View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy6 analystsis eftr a buy · eftr analyst rating
Strong Buy
0
Buy
6
Hold
0
Sell
0
Strong Sell
0
12-Month Price Target
$1.00Low
$0.00Current
$5.50Avg Target2749900.00% upside
$10.00High
eftr price target · eftr 12 month forecast

Total: 6 · Buy rate: 100.0%

The EFTR analyst consensus is Buy, based on ratings from 6 Wall Street analysts over the past 3 months. The average 12-month price target is $5.50, representing +2749900.00% upside from the current price of $0.00.

Stock Performance

Full History
1D+0.00%
1W+0.00%
1M-60.00%
3M+0.00%
YTD+0.00%
1Y+0.00%
5Y-100.00%

About eFFECTOR Therapeutics, Inc.

CEODavide Ruggero
IPO DateMar 1, 2021
Employees14
CountryUS

eFFECTOR Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidat…

what is effector therapeutics, inc. · eftr stock overview · effector therapeutics, inc. company profile · who is effector therapeutics, inc. ceo · eftr OTC · effector therapeutics, inc. headquarters · effector therapeutics, inc. business segments

About Stock Overview & Key Data

eFFECTOR Therapeutics, Inc. (EFTR) is a Healthcare company in the Biotechnology industry, listed on OTC since Mar 1, 2021. As of the latest trading session, EFTR stock price is $0.00, with a market capitalization of $941. The stock has returned +0.00% over the past 12 months and +0.00% year-to-date.

According to 6 Wall Street analysts, the consensus rating for eFFECTOR Therapeutics, Inc. stock is Buy, with an average 12-month price target of $5.50. In fiscal year 2023, eFFECTOR Therapeutics, Inc. reported revenue of — and net income of -$35.8M. For detailed data — including eFFECTOR Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, eFFECTOR Therapeutics, Inc. (EFTR) stock price is $0.00. The stock is traded on OTC under the ticker symbol EFTR. The 52-week range is $0.00 – $0.01.

EFTR stock priceEFTR quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice